BRD4 and ovarian carcinoma: It is possible that, just as with TNBC, the amplification of BRD4 in HGSOC may lead to a shift in the splicing ratio of the two BRD4 isoforms resulting in BRD4-S overactivation that drives ovarian cancer pathogenesis and contribute to patients’ poor prognosis (Fig. 2).